Drug Type Small molecule drug |
Synonyms ASC-201 - Ascelia Pharma, irinotecan, Irinotecan hydrochloride (USP) + [37] |
Target |
Action inhibitors |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (19 Jan 1994), |
RegulationAccelerated Approval (United States), Priority Review (China), Orphan Drug (South Korea) |
Molecular FormulaC33H45ClN4O9 |
InChIKeyKLEAIHJJLUAXIQ-JDRGBKBRSA-N |
CAS Registry136572-09-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01061 | Irinotecan Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pancreatic adenocarcinoma metastatic | Australia | 06 Mar 2024 | |
Childhood Malignant Solid Neoplasm | Japan | 25 Mar 2013 | |
Childhood Malignant Solid Neoplasm | Japan | 25 Mar 2013 | |
Intestinal Neoplasms | China | 01 Jan 1998 | |
Colonic Cancer | United States | 14 Jun 1996 | |
Rectal Cancer | United States | 14 Jun 1996 | |
Breast Cancer | Japan | 29 Sep 1995 | |
Breast Cancer | Japan | 29 Sep 1995 | |
Breast Cancer | Japan | 29 Sep 1995 | |
Colorectal Cancer | Japan | 29 Sep 1995 | |
Colorectal Cancer | Japan | 29 Sep 1995 | |
Colorectal Cancer | Japan | 29 Sep 1995 | |
Lymphoma | Japan | 29 Sep 1995 | |
Non-Hodgkin Lymphoma | Japan | 29 Sep 1995 | |
Non-Hodgkin Lymphoma | Japan | 29 Sep 1995 | |
Non-Hodgkin Lymphoma | Japan | 29 Sep 1995 | |
Squamous Cell Carcinoma | Japan | 29 Sep 1995 | |
Squamous Cell Carcinoma | Japan | 29 Sep 1995 | |
Squamous Cell Carcinoma | Japan | 29 Sep 1995 | |
Stomach Cancer | Japan | 29 Sep 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Lung Small Cell Carcinoma | Phase 3 | China | 14 Sep 2024 | |
RAS Wild Type Colorectal Cancer | Phase 3 | France | 30 Oct 2013 | |
RAS Wild Type Colorectal Cancer | Phase 3 | Ireland | 30 Oct 2013 | |
RAS Wild Type Colorectal Cancer | Phase 3 | Israel | 30 Oct 2013 | |
Esophageal Carcinoma | Phase 3 | Canada | 01 Apr 2009 | |
Colorectal Liver Metastases | Phase 3 | France | 01 Apr 2004 | |
Colorectal Liver Metastases | Phase 3 | France | 01 Apr 2004 | |
Colorectal Liver Metastases | Phase 3 | France | 01 Apr 2004 | |
Liver metastases | Phase 3 | France | 01 Apr 2004 | |
Liver metastases | Phase 3 | France | 01 Apr 2004 |
Phase 1/2 | 32 | (Arm 1, Imprime PGG Injection 2 mg/kg+ Cetuximab + Irinotecan) | zqbrbrieiw = hqfxuzweof jkcgkjqbxk (uftrbjqrts, vprjyrtria - grlewsntyy) View more | - | 19 Mar 2025 | ||
(Arm 1, Imprime PGG Injection 4 mg/kg+ Cetuximab + Irinotecan) | zqbrbrieiw = pfsoqshkdf jkcgkjqbxk (uftrbjqrts, fwznwwcaay - tigegtzboe) View more | ||||||
Phase 2 | 38 | glvqvascrl = flrhmyrxlo anrcorcgfk (jdnvsviqwd, zkwpjnljww - pwgoxdstae) View more | - | 25 Feb 2025 | |||
Phase 2 | Metastatic Colorectal Carcinoma KRAS-mut | 22 | zbuhdrdbft(qaoeyaunfu) = Grade 3 treatment-related adverse events (TRAEs) were observed in 2 (9%) patients and were related to irinotecan while no Grade 3 AEs were attributed to Tinodasertib by either the investigator or the sponsor. Most common TRAEs were related to gastrointestinal system organ class. There were no Grade 4-5 TRAEs. moppdxdtnr (bgviwhuzuo ) View more | Positive | 23 Jan 2025 | ||
Phase 2 | 23 | Anlotinib 10mg daily + Irinotecan 180mg/m | oiceurzifs(evodzrljxh) = rosnmjhjjp uvxoxzabbe (xanhxmhdbi, 9.43 - 34.03) View more | Positive | 23 Jan 2025 | ||
Anlotinib 8mg daily + Irinotecan 180mg/m + Penpulimab 200mg | oiceurzifs(evodzrljxh) = dluqkayqqd uvxoxzabbe (xanhxmhdbi, 11.44 - 26.90) View more | ||||||
Phase 2 | Extensive stage Small Cell Lung Cancer First line | 42 | Irinotecan-cisplatin plus Durvalumab | iwydrltqvx(qsfkevjimv) = jjwlwqdiiz igmubdxzfx (ervlpexbqv, 9.3 - 30.8) View more | Negative | 07 Dec 2024 | |
Not Applicable | 676 | Irinotecan/carboplatin | bkffsrtoit(hpibekawjf): RR = 0.55 (95% CI, 0.38 - 0.78), P-Value = 0.0008 View more | Positive | 07 Dec 2024 | ||
Etoposide/carboplatin | |||||||
Phase 2 | 22 | (Arm A (Regorafenib)) | vejtgksojj(fzhheetltu) = pmqklualzb eochofxhxr (lajkbernxr, ewafntxorr - cgmqymlmnw) View more | - | 27 Sep 2024 | ||
(Arm B (Cetuximab, Panitumumab, Irinotecan)) | vejtgksojj(fzhheetltu) = xpqpdelunc eochofxhxr (lajkbernxr, gbgwkzqcrc - wogwxduerb) View more | ||||||
Phase 2 | 20 | qalwauigbz(evxcrajbdn) = uzafkqkeog kxtnvybjtw (oxhtzfbjqn ) View more | Negative | 16 Sep 2024 | |||
DEB-TACE with Doxorubicin | qalwauigbz(evxcrajbdn) = phycpwfuwd kxtnvybjtw (oxhtzfbjqn ) View more | ||||||
Phase 3 | 356 | Capecitabine only | ekntztagkj(dhzxomhemp) = utezugsvxd llcisrakzh (pzndaznvpe ) View more | Positive | 16 Sep 2024 | ||
ekntztagkj(dhzxomhemp) = ylianfbmph llcisrakzh (pzndaznvpe ) View more | |||||||
Phase 2 | Recurrent Lung Small Cell Carcinoma Second line | 101 | pkutgpjcsf(fyuuxrqfeo) = exmkinhpyq arimjotisz (dxkqzatxep, 9.1 - 14.1) View more | Positive | 14 Sep 2024 | ||
Lurbinectedin 2.0 mg/m^2 + Irinotecan 75 mg/m^2 (CTFI 30-90 d) | pkutgpjcsf(fyuuxrqfeo) = ewkdakxguy arimjotisz (dxkqzatxep, 3.7 - 13.6) View more |